Precision Medicine of Thyroid Cancer
Since the progress and prevalent of the next-generation sequencing (NGS) and target therapy in these years, the treatment of the advanced thyroid cancer has a lot of change. Initially, multikinase inhibitors (MKIs) were used for the progressive radioiodine-refractory differentiated thyroid carcinoma (rrDTC) cases only. It’s more like a salvage treatment rather than a curative therapy. Fortunately, combining with the advancement of the molecular pathology and the NGS, there are more and more tyrosine kinase inhibitors proposed to be used in different thyroid cancer patients. The role of these target therapy is shift from the salvage option to as an inductive therapy gradually. Now, for the thyroid cancer treatment, we not only has surgeon performed ultrasonography, excellent surgical skills, but also focused on precision medicine to pursue the specific treatment modalities for the different cancer cases.
Special Features
An advanced thyroid cancer case with bRAF v600e mutation was treated with target therapy (Tafinar and Mekinist) for 6 months. The target therapy was used as an induction therapy. Then the patient received the surgery and the following RAI treatment with larynx and bilateral recurrent laryngeal nerves preservation.
Specialist
Keng-Ming Change Yun-Ying She Yaoh-Shiang Lin